No increased CV, death risk with ticagrelor plus proton pump inhibitor therapy after PCI

Concomitant proton pump inhibitor plus ticagrelor monotherapy after PCI does not increase risk for all-cause death or an adverse CV event, in contrast with conventional post-PCI antiplatelet therapy, researchers reported.In a post hoc analysis of the GLOBAL LEADERS trial, researchers found that patients taking a proton pump inhibitor (PPI) treated with the conventional post-PCI treatment strategy of 12-month dual antiplatelet therapy followed by aspirin monotherapy were more likely to experience all‐cause mortality, MI, stroke or repeat revascularization compared with those not taking a PPI.“InRead More

Related Articles